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HEMATOPOIESIS AND STEM CELLS
IFN-g causes aplastic anemia by altering hematopoietic stem/progenitor
cell composition and disrupting lineage differentiation
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and Howard A. Young1
1Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD; 2Laboratory of Animal Science, Leidos
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Key Points
• IFN-g alone leads to aplastic




• The inhibitory effect of IFN-g
on hematopoiesis is intrinsic
to hematopoietic stem/
progenitor cells.
Aplastic anemia (AA) ischaracterizedbyhypocellularmarrowandperipheral pancytopenia.
Because interferongamma(IFN-g) canbedetected inperipheralbloodmononuclearcellsof
AA patients, it has been hypothesized that autoreactive T lymphocytes may be involved in
destroying the hematopoietic stem cells.We have observedAA-like symptoms in our IFN-g
adenylate-uridylate–rich element (ARE)–deleted (del) mice, which constitutively express
a low level of IFN-g under normal physiologic conditions. Because no T-cell autoimmunity
was observed,wehypothesized that IFN-gmaybe directly involved in the pathophysiology
of AA. In these mice, we did not detect infiltration of T cells in bone marrow (BM), and the
existing T cells seemed to be hyporesponsive. We observed inhibition in myeloid pro-
genitor differentiation despite an increase in serum levels of cytokines involved in
hematopoietic differentiation and maturation. Furthermore, there was a disruption in
erythropoiesis and B-cell differentiation. The same phenomena were also observed
in wild-type recipients of IFN-gARE-del BM. The data suggest that AA occurswhen IFN-g
inhibits the generation of myeloid progenitors and prevents lineage differentiation, as opposed to infiltration of activated T cells.
These results may be useful in improving treatment as well as maintaining a disease-free status. (Blood. 2014;124(25):3699-3708)
Introduction
Aplastic anemia (AA) is a life-threatening disease characterized
by hypocellular marrow and pancytopenia as a result of reduction in
hematopoietic progenitor and stem cells (HSPCs). Usually, AA is a
result of HSPC destruction targeted by autoreactive cytotoxic T cells.
Oligoclonal expansion of T-cell receptor (TCR) Vb subfamilies and
interferon gamma (IFN-g) can be detected in peripheral blood
mononuclear cells of these patients. Althoughmany factors have been
implicated in autoreactive T-cell activation, no conclusive causes have
been identified. In,10% of AA patients, the disease mechanism has
a genetic basiswith inheritedmutations or polymorphism in genes that
repair or protect telomeres. These defects result in short telomeres,
which dramatically decrease the proliferative capacity of HSPCs.1,2
Currently, themost effective therapy forAA is hematopoietic stem cell
transplantation; however, ,30% of patients have a suitable HLA-
matched donor.3 Because most AA patients are immune mediated,
when a histocompatible donor is unavailable, patients undergo im-
munosuppressive therapy (IST) consisting of antithymocyte globulin/
antilymphocyte globulin with cyclosporine. This treatment results in
a significant reduction in the number of circulating T cells followed by
disease resolution.4,5
Several recent studies have determined that a high percentage of
AA patients show a T→A single nucleotide polymorphism at position
1874 of intron 1 in the IFN-g gene compared with normal controls,
resulting in higher levels of IFN-g expression.6-8 Thus, it was sug-
gested that higher IFN-g expression levels may correlate with a
greater risk of developing AA. Additional evidence suggested that
IFN-g 1874 TT, a high IFN-g expression genotype is a predictor of
a better response to IST in AA patients.9 Moreover, Dufour et al10
found that AA patients who responded to IST had a significantly
higher frequency of CD31/IFN-g1 cells than normal controls (561 vs
50 cells permilliliter),which implied that ISTmaynot fully clear IFN-g
from patients. Blockade of IFN-g in a culture with marrow from
IST responders showed an increase in burst-forming unit erythroid.
Therefore, it was proposed that patients with acquired AA would
benefit from IST combinedwith IFN-g neutralization treatment. These
studies suggest that IFN-g contributes significantly to AA pathology
and may also be a therapeutic target. Although several studies
have explored this question, their models used IFN-g that was either
added exogenously or expressed by non-IFN-g–expressing cells.11,12
Therefore, our laboratory developed an animal model whereby IFN-g
is expressed by natural killer (NK) andT cells,which normally express
IFN-g and will allow us to better investigate the mechanisms of
how IFN-g contributes to the development of AA. Our BALB/c
mouse model contains a 162-nucleotide targeted substitution in the
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39 untranslated region of the IFN-g gene that eliminates the adenylate-
uridylate–rich element (ARE) of the IFN-gmessenger RNA (mRNA)
(mice are designated as ARE-del). The ARE of the IFN-g mRNA
mediates the destabilization of the mRNA.13 Thus, the deletion
increases the half-life of IFN-g mRNA and results in constant ex-
pression of IFN-g. Although we did not observe an active T-cell
response in the ARE-del mice, these animals exhibited an AA-like
phenotype, including hypocellular marrow and pancytopenia.
Therefore, we believe that IFN-g plays a role in the AA pathology
in these mice. In this study, we found that AA in ARE-del mice was
the result of constant exposure to low levels of IFN-g by inhibiting
the differentiation of multipotent progenitors (MPPs) to myeloid




The 162-neucleotide ARE sequence was replaced by electroporation of the
IFN-g/Neo cassette into the DY380 bacterial strain with a bacterial antigen
complex containing the IFN-g gene. A 9.9-kb sequence containing the
recombined locus was retrieved from the bacterial antigen complex and
cloned into a pBR322 plasmid. The modified pBR322 plasmid was introduced
into an embryonic stem cell line by gene targeting to generate chimeric mice.
The Neo cassette removal was accomplished by crossing the chimeras with
b-actin Cre-transgenic mice. Animals used in this study were 3 to 8 weeks old.
Animal care was provided in accordance with the procedures outlined in the
Guide for Care and Use of Laboratory Animals.
Flow cytometry
The following antibodies were used in this study: anti-NKp46, CD3, IFN-g,
Sca-1, c-Kit, interleukin (IL)-7Ra, CD16/32, CD71, CD19, and B220 (eBio-
science), CD34 and CD135 (BD Biosciences PharMingen), and CD43, CD44,
Gr-1, CD25, Ter119, andMac-1 (BioLegend). For NK cell, T-cell, and lineage
analysis, whole bone marrow (BM) cells were used. For HSPCs, immunophe-
notype analysis lineage-negative cells were selected by using the Lineage Cell
Depletion Kit (Miltenyi Biotec) before antibody staining. Dead cells were
excluded by using Fixable Viability Dye eFluor 660 (eBioscience). An LSRII
flow cytometer (BD Biosciences) was used for acquiring data, and results were
analyzed by using FlowJo software (TreeStar).
BM transplantation
For BM transplantation, recipient wild-type (WT) or ARE-del mice received
400 radof radiation andwere injectedwith 53106BMcells fromWTmice. For
the chimera model, recipient WT Balb/c mice were treated with trimethoprim-
sulfomethoxazole in the drinking water 1 week before receiving 900 rad of
radiation and were injected with 106 BM cells from either WT or ARE-del
mice. Phenotypes were examined 8 weeks after BM reconstitution.
IFN-g–neutralizing antibody treatment
WT and ARE-del mice were injected intraperitoneally with 200 mg of IFN-
g–neutralizing antibody (XMG-6, generously provided byDrGiorgio Trinchieri)
or control antibody (GL113) in 100mL phosphate-buffered saline once per week
for 8 weeks. Animals were retro-orbitally bled once every 2 weeks for complete
bloodcount analysis.BMcell immunophenotypeswereexaminedat theendof the
treatment period.
Statistical analysis
Data are reported as mean6 standard deviation. Statistical significance was
determined by two-tailed unpaired Student t test. Differenceswere considered
significant if P, .05. All the statistical analyses were performed by using the
GraphPad Prism statistical package.
Results
ARE-del mice exhibit an AA phenotype resembling
human disease
Because the absence of the ARE region stabilizes IFN-gmRNA, we
were able to detect increased IFN-gmRNA expression in BM, liver,
thymus, spleen, lungs, and kidneys (Figure 1A). Under normal
physiological conditions, we detected measureable IFN-g in the
serum at;40 pg/mL (Figure 1B). Although measurable, IFN-g
serum levels less than 50 pg/mL are considered low in human
serum.14 Indeed, ARE-delmice have several phenotypes consistent
with human AA. The hypocellular marrow in severe AA is defined
as #50% of the BM cellularity of healthy individuals.15 In ARE-
del mice, total BM cellularity was ;25% that of the WT mice
(Figure 1C). Histopathologic examination of ARE-del BM con-
firmed that cellularity was significantly decreased at 3 weeks of age
with a marked decrease in megakaryocytes. BM cellularity was
further decreasedwith a loss ofmyeloid cells at week 6 (Figure 1D).
As a consequence of the BM hypocellularity, ARE-del mice ex-
hibited another hallmark of AA, peripheral blood pancytopenia
with lowwhite blood cell (WBC),RBC, andplatelets counts (Table 1).
On the basis of these observations, we used this mouse model to
determine how a low level of IFN-g contributes to AA pathology.
AA phenotype in ARE-del mice is not caused by activated
T cells in the BM
To rule out T-cell–mediated destruction of HSPCs, we measured the
levels of T-cell infiltration into the BM. The slight increase in the
percentage of T cells (;0.1%) observed in ARE-del BMwas a result
of low BM cell number, since the absolute T-cell number was sig-
nificantly lower (Figure 1E). To evaluate the function of BMT cells,
we measured cytokine production after stimulating with TCR
agonists (anti-CD3/anti-CD28 antibodies). The cytokine levels ex-
pressed by ARE-del BM T cells after TCR stimulation were
significantly lower than in WT mice, except tumor necrosis factor
alpha (TNF-a) (Figure 1F). We also observed the same hypores-
ponsiveness in ARE-del mice spleen and lymph node T cells after
a mixed lymphocyte reaction (supplemental Figure 1, available on
the BloodWeb site). Because an abnormal T-cell repertoire has been
reported in AA patients, we characterized the ARE-del BM T-cell
repertoire by flow cytometric methods using antibodies that detect
different TCRVb chains.16-18 Abnormal expansions of Vb-expressing
T cells were defined as values greater than the mean obtained fromWT
animals plus23standarddeviationaspreviouslydescribed.19Although
we observed a slight expansion in 4 Vb subfamilies in CD4 T cells and
2 Vb subfamilies in CD8 T cells in ARE-del BM, both the percentage
of expansion and the expansion ratio (CD4: 27%, CD8: 17%) in ARE-
del mice are much lower compared with that previously reported in AA
patients (expansion ratio, 40% to 80%) (supplemental Figure 2).17,19 In
addition, histopathological examination of the spleen, thymus, and
lymph nodes revealed structural damage and apparent atrophy
(supplemental Figure 3), a characteristic reported in congenital
AA animal models, which implies that ARE-del mice are severely
immunodeficient.20 To summarize, the absence of T-cell infiltration in the
BM, nonresponsive BM T cells, no abnormal BM T-cell expansion, and
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general immunodeficiency indicate that T cells are unlikely the cause of
AA in ARE-del mice.
IFN-g signaling is detected in ARE-del BM cells
To test the hypothesis that IFN-gwas responsible for theAAphenotype
in ARE-del mice, we first identified the source of IFN-g in ARE-del
BM. We detected IFN-g expression in NK and T cells without
additional stimulation (Figure 2A), indicating that IFN-g is present
in the BM microenvironment under basal conditions. We were not
able to detect IFN-g expression from lineage-negative cells, which
are progenitor-enriched cells, B cells, and myeloid cells in BM (sup-
plemental Figure 4). IFN-g affects cells by ligand-receptor interaction-
triggered JAK/STAT signaling. We found IFN-g receptor expressed
on all lin2cKit1Sca1hi (LSK) and lin2cKit1Sca12 (LK) cells by using
confocal microscopy (Figure 2B). This result suggests that HSPCs
could be direct targets of IFN-g. To determinewhether BMcells could
respond to IFN-g, we evaluated STAT1 phosphorylation in un-
stimulated BM cells from both WT and ARE-del mice and could
detect STAT1 phosphorylation only in ARE-del BM cells (Figure 2C).
These data support the hypothesis that IFN-g in ARE-del BM
induces JAK/STAT signaling in HSPCs and contributes to BM
failure.
IFN-g disrupts the differentiation of MPPs to
myeloid progenitors
To determine the impact of IFN-g on hematopoiesis, we compared
the total number of immunophenotypic HSPCs present in WT and
ARE-del BM. We saw a dramatic decrease in the cell numbers of
common myeloid progenitors (CMPs) (fourfold), granulocyte/
monocyte progenitors (GMPs) (fourfold), and megakaryocyte/
erythrocyte progenitors (MEPs) (eightfold) in ARE-del mice.
There were no significant differences in the cell numbers of short-term
hematopoietic stem cells (ST-HSCs), MPPs, and common lymphoid
Table 1. ARE-del mice have profound pancytopenia and anemia (n5 7)
WT (mean 6 SD) ARE-del (mean 6 SD) P
WBC, 3103/mL 8.862 6 1.44 2.42 6 1.94 .05
RBC, 3106/mL 9.243 6 0.1 2.147 6 1.98 .02
Platelets, K/mL 953 6 102 243.8 6 145 .016
Blood was collected via cardiac puncture into collecting tubes containing EDTA.
Complete blood count (CBC) was done within 3 hours after collection.
Figure 1. T cells are not the cause of the AA-like phenotype in ARE-del mice. (A) Total RNA was extracted from tissues. Equal amounts of RNA were reverse transcribed
into mRNA. IFN-g mRNA levels were detected by using real-time polymerase chain reaction. Data were normalized against glyceraldehyde-3-phosphate dehydrogenase mRNA
levels and calculated relative to IFN-g expression levels in WT tissue set to 1 (n 5 3). (B) Serum from animals was analyzed by using a cytometric bead array to determine IFN-g
levels (n 5 7). (C) Single-cell suspensions of BM cells were prepared and counted, and total cell numbers are shown (n 5 7). (D) Sternums from 6 WT and 6 ARE-del mice were
fixed and stained with hematoxylin and eosin. Depicted here are representative photographs from 1 set of animals. (E) Seven-color flow cytometry analyses were performed on
total BM cells. T cells were gated on the live NKp46–CD11b–B220–Gr1–CD31 population. The bar graphs show both the total cell number and percentage of live cells (n 5 4). (F)
T cells were selected from BM. The function of T cells was determined by the intensity of cytokine responses against TCR agonists (anti-CD3/anti-CD28 antibodies). Cytokine
levels in the medium were measured 6 hours after stimulation by using a cytometric bead array. The bar graphs displays the concentration of each cytokine measured (n 5 4). All
experiments were performed at least 3 times. Results are expressed as mean 6 standard deviation (SD). *P , .05; **P , .01; ***P , .001; ****P , .0001. SPL, spleen.
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progenitors (Figure 3A). Because IFN-g has been known to suppress
hematopoiesis,11 we were surprised to see an increase in long-term
HSCs (LT-HSCs) (2.5-fold). Thus, we confirmed the increase of
LT-HSCs by using the SLAMmarker, CD150, which is co-expressed
onHSCswith self-renewal capability.21We observed a fourfold increase
in the cell number of lin–cKit1Sca1hiCD34–Flt3–CD1501 (Figure 3B).
To confirm that the decrease inCMPs,GMPs, andMEPs is correlated to
a decrease in function, we examined the ability of these progenitors
to form colonies. We found that the total number of burst-forming unit
erythroid, colony-forming unit (CFU)-granulocyte, -erythrocyte,
-macrophage, and -megakaryocyte (CFU-GEMM),CFU-granulocyte,
-macrophage (CFU-GM), CFU-megakaryocyte (CFU-M), and CFU-
granulocyte (CFU-G)progenitorswere significantly lower inARE-del
mice, demonstrating that these progenitors are not only decreased in
number but are also decreased in function (Figure 3C). These data
indicate that the generation ofCMPs,GMPs, andMEPs is significantly
inhibited in ARE-del mice. The block in myeloid progenitor pro-
duction could have a profound impact on the generation of blood cells,
and thus contribute to the pathology of pancytopenia in AA.
IFN-g inhibits LK population proliferation
IFN-g induces PD-L1 expression on T cells, NK cells, macrophages,
myeloid cells, B cells, epithelial cells, and endothelial cells, and
PD-L1 binding to its receptor PD-1 induces apoptosis.22 Because this
mechanism could account for the loss in CMPs, GMPs, andMEPs in
ARE-del mice, we evaluated apoptosis in ARE-del BM cells.We did
not detect a significant increase in apoptosis in either LSKor LKcells
in ARE-del BM compared with WT (Figure 3D). These results were
confirmed when we evaluated apoptotic cells by using the terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling
assay (supplemental Figure 5A). Because IFN-g has been shown to
inhibit HSPC proliferation in vitro, this inhibition may be the result
of the decrease in HSPCs. We evaluated HSPC proliferation by
measuring Ki-67 and found that Ki-67 expression level in the LSK
population of ARE-del micewas twofold higher comparedwithWT,
whereas in the LK population, the level was 30% lower (Figure 3E).
The inhibition of LK proliferation by IFN-g was also observed in
vitro when we evaluated the proliferation of CMPs, GMPs, andMEPs
cultured with IFN-g. CMPs cultured with IFN-g had a significantly
lower proliferation rate compared with those cultured with medium
only. Although the trend was not statistically significant, we observed
a trend toward inhibition ofGMPproliferationby IFN-g. Interestingly,
the inhibitory effect of IFN-g onMEPswas observed only inARE-del
mice (supplemental Figure 5B). Together, these data suggest that
the hypocellularity in ARE-del mice BM was a result of disruption
in CMP generation and a reduction in the proliferative potential of
the LK population.
IFN-g disrupts multilineage differentiation
To determine whether cell lineages were affected in ARE-del mice,
we examined the development of erythroid, myeloid, and lymphoid
cells. We first examined BM cells with anti-CD71 and Ter119
antibodies to identify different stages of erythroid differentiation.23
There was a twofold increase in the percentage of immature eryth-
rocytes, proerythroblasts, and polychromatophilic erythroblasts and
a twofold decrease in the mature erythrocytes and orthochromatophilic
erythroblasts in ARE-del BM compare withWT (Figure 4A).We con-
firmed these results by using cell size, CD71, and Ter119.24
Figure 2. IFN-g and IFN-g signaling are detected in
ARE-del BM. (A) T cells were gated on the live
NKp46–CD11b–B220–Gr1–CD31 population, and NK cells
were gated on the live NKp461CD11b–B220–Gr1–CD3–
population. IFN-g expression by BM NK and T cells was
detected by using intracellular cytokine staining. Dot plots
are representative of 1 set of 4 experiments. (B) Total BM
cells from WT and ARE-del mice were sorted into
LSK (LT-HSCs, ST-HSCs, and MPPs) and LK (CMPs,
GMPs, and MEPs) populations and centrifuged onto
slides. The cells were then stained with antibody against
IFN-g receptor. The expression of IFN-g receptor was
captured with a Zeiss LSM 710 confocal microscope. (C)
Total protein was extracted from untreated WT and ARE-
del BM. Proteins were detected by western blotting with
antibody against phosphorylated Stat1 (pSTAT1) tyrosine
701 residue. Stat1 and actin were used as loading con-
trols. Positive control (PC) is protein extracted from
WT splenocytes stimulated with IFN-g for 15 minutes.
DAPI, 4,6 diamidino-2-phenylindole. FSC, forward side
scatter.
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Specifically, we observed an increase, although not significant, in
the percentage of the immature erythrocytes ProE, EryA, and EryB
and a twofold decrease in the mature erythrocytes EryC in ARE-del
BM (Figure 4A). When we calculated the absolute cell number, we
found that there was a ninefold decrease in the total output of ery-
throid cells in ARE-del mice. These results suggest that immature
erythrocytes in ARE-del mice fail to differentiate into mature cells,
resulting in a severe decrease in the cell output thatwouldultimately lead
to anemia.
When investigating B-cell lineage differentiation, we found there
was no difference in the percentage of PrePro B cells (the immature
early B cells arising from common lymphoid progenitors) and ProB
cells (the early B cells derived from PreProB cells). However, we
found a twofold reduction in the percentage of PreB (the early B cells
differentiated from ProB cells) (Figure 4B). This result implies
a disruption in early B-cell differentiation. The decrease in the
percentage of PreB cells in ARE-del mice has a profound impact on
the output of early B cells and the generation of mature B cells. The
absolute cell numbers of PreB and mature B cells were reduced ap-
proximately eightfold (Figure 4B). In contrast, we did not observe any ef-
fect on myeloid differentiation, although ARE-del mice had a threefold
reduction in the total number of myeloid cells in BM (Figure 4C). To
summarize, IFN-g impairs multilineage differentiation and severely
reduces the output of mature erythrocytes, B cells, and myeloid cells,
which would account for hypocellular marrow and pancytopenia.
AA phenotype in ARE-del mice is not a result of a cell
nonautonomous effect of IFN-g on the BM microenvironment
Next, we determined whether the BM failure observed in ARE-del
micewas a result of a cell nonautonomous effect of IFN-g on the BM
microenvironment, which could impair the ability of niche cells to
Figure 3. Constant exposure to IFN-g alters the
composition of HSPCs. (A) HSPC composition was
gated on lineage-negative BM cells by using flow cytometry,
LT-HSCs (lin–cKit1Sca1hiCD34–Flt3–), ST-HSCs (lin–cKit1
Sca1hiCD341Flt3–), MPPs (lin–cKit1Sca1hiCD341Flt31),
common lymphoid progenitors (CLPs; lin–cKitintSca1intIL-
7R1), CMPs (lin2cKit1Sca1–CD341CD16/32int), GMPs
(lin2cKit1Sca12CD341CD16/32hi), and MEPs (lin2cKit1
Sca1–CD34–CD16/32lo) (n 5 7). The bar graph shows the
total cell number of each cell type. Density plots are
representative of HSPC gating from 1 set of 4 ex-
periments. (B) The lin–cKit1Sca1hiCD34–Flt31CD1501
population was used to confirm HSC composition. The
bar graph shows the total cell number (n 5 5). (C) The
function of CMPs, GMPs, and MEPs was analyzed by
using a colony-forming assay. Lineage-negative BM cells
were plated in triplicate, and the colonies were counted
after culture for 7 days. The numbers of each colony are
shown. (D) Apoptosis in HSPC was assessed by using
Annexin V staining and Fixable Viability Dye eFluor 660.
The Annexin V–positive/Viability Dye–negative popula-
tion represents apoptotic cells. The bar graph shows the
percentage of apoptotic cells in the LSK or LK population
(n 5 4). Density plots are representative of 1 set of 4
experiments. (E) The proliferation of HSPCs was de-
termined by the expression level of Ki-67. The bar graph
shows the medium fluorescent intensity (MFI) of Ki-67
cells in the LSK or LK population. Histograms are rep-
resentative of 1 set of 4 experiments. All experiments were
performed at least 3 times. Similar results were obtained
from 3 different experiments. Results are expressed
as mean 6 SD. *P , .05; **P , .01; ***P , .001;
****P , .0001. N.D., not detectable.
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support normal hematopoiesis. First, we evaluated the levels of
serum hematopoietic cytokines produced by stromal cells. Se-
rum levels of Flt3 ligand (Flt3L) (twofold), stem cell factor (SCF)
(1.5 fold), IL-3 (threefold), and erythropoietin (EPO) (sevenfold)
were all significantly higher in ARE-del mice (Figure 5A). IL-6
levels were also higher in ARE-del mice, although not significantly
higher. Granulocyte macrophage colony-stimulating factor was
not detectable in the serum of ARE-del and WT mice, which
demonstrates that BM niche cells in ARE-del mice were capable
of secreting cytokines required to maintain functional hema-
topoiesis. Furthermore, it suggests that AA phenotype in ARE-
del mice was not a result of a deficiency in hematopoietic
cytokines.
We then investigated whether the BM niche in ARE-del mice is
able to support hematopoiesis by using a BM chimera model. We
transferred BM cells from healthy WT mice into ARE-del mice and
examined their phenotype 8weeks after reconstitution. Similar to the
human disease, BM transplantation reversed the AA phenotype in
WT BM-reconstituted ARE-del (WT.ARE-del) chimeras. The BM
cellularity in WT.ARE-del chimeras was comparable to the WT
BM-reconstituted WT (WT.WT) chimeras (Figure 5B). Although
WBC, RBC, and platelet counts in WT.ARE-del chimeras were
slightly lower than in WT.WT chimeras, they were all within the
normal range (Table 2). WT BM transplantation was able to restore
the HSPC composition to one more closely resembling that in WT
(Figure 5C). Furthermore, WT BM transplantation also resolved the
blocks in erythropoiesis and early B-cell differentiation observed in
the ARE-del mice (Figure 5D). These data show that the BM niche in
ARE-del mice is functional and able to support normal hematopoiesis.
ARE-del BM-reconstituted WT (ARE-del>WT) chimeras exhibit
an early AA phenotype 8 weeks after BM reconstitution
The ability ofWTBM-restoring normal hematopoietic development
in the ARE-del mice indicates that the inhibitory effect of IFN-g on
hematopoiesis may be cell intrinsic. To confirm this hypothesis, we
transplanted the ARE-del BM cells into lethally irradiated WT
BALB/c mice. We then analyzed the phenotype 8 weeks after BM
reconstitution. Complete blood count analysis revealed that ARE-
del.WT chimeras had a slight decrease in WBC and RBC counts
and severe thrombocytopenia, which, in the human disease, is the
first sign of AA followed by anemia and pancytopenia (Table 3).25
In addition, ARE-del.WT chimeras had significantly lower BM
cellularity than WT.WT chimeras (Figure 6A). These results show
Figure 4. Constant exposure to IFN-g interrupts RBC and B-cell differentiations. Total BM cells were stained with fluorochrome-conjugated antibodies for lineage
differentiation analysis. (A) Different developmental stages of RBCs were gated according to the expression levels of Ter119 and CD71 (R1: proerythroblasts,
Ter119medCD71high; R2: early basophilic erythroblasts, Ter119highCD71high; R3: polychromatophilic erythroblasts, Ter119highCD71med; R4: orthochromatophilic erythroblasts,
Ter119highCD71lo). ProE cells are gated on the CD71hi and Ter119low population. Ter119hi population was then further defined on the basis of the expression levels of CD71
and cell size into EryA (CD71highFSChigh), EryB (CD71highFSClow), and EryC (CD71lowFSClow). (B) Live IgM–B2201 population in BM was measured by using CD43 and CD19
to define PreProB (CD431CD19–). PreB (B2001CD43–) and ProB (B2201CD431) populations were gated on live IgM– population in BM using CD43 and B220. Mature B cells
were gated on a live IgM1B2201 population. (C) Myeloid cells in BM were gated on the Mac11CD11b1 population. Dot plots are representative of 1 set of multiple
experiments. Bar graphs show the percentage of total live BM cells and the total cell numbers of each cell type (n 5 5). Similar results were obtained from 4 different
experiments. Results are expressed as mean 6 SD. *P , .05; **P , .01; ***P , .001; ****P , .0001.
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that ARE-del.WT chimeras were in the early stage of disease, which
allowed us to investigate T-cell involvement in the initiation of AA.
Similar to that observed in ARE-del mice, we observed a slight
increase (;0.2%) in the T-cell percentage of total BM cells in ARE-
del.WT chimeras. However, there was no difference in the absolute
T-cell number (Figure 6B). When stimulated with TCR agonists, the
cytokine responses of ARE-del.WT BM T cells were either lower
than or equivalent to those of WT.WT chimeras, except IFN-g
(Figure 6C). These findings demonstrate that ARE-del.WT BM
T cells were not activated and were not involved in disease initiation.
When we examined the BM progenitors by immunophenotype, we
observed HSPC composition in ARE-del.WT BM similar to that in
ARE-del BM: high LT-HSC and low CMPs, GMPs, and MEPs
(Figure 6D).We observed a block in erythroid development similar to
that inARE-delmice but to a lesser extent (Figure 6E). Together, these
data indicate that IFN-g results in a cell-intrinsic defect in HSPCs that
leads to inhibition of hematopoiesis and disruption in erythropoiesis.
IFN-g–neutralizing antibody treatment reverses HSPC
composition and restores erythropoiesis
To confirm the inhibitory effect of IFN-g on hematopoiesis in ARE-
del mice, we blocked the effect of IFN-g by treating with IFN-
g–neutralizing antibodies once per week for 8 weeks and then
analyzed the phenotype ofARE-delmice. The treatmentwas performed
on 3-week-old ARE-del mice, which exhibited thrombocytopenia but
not anemia and were healthy enough to receive injections. Mice were
bled once every2weeks tomonitor the platelet levels.More than 50%of
ARE-del mice receiving control antibody died during the treatment
period, which resulted in an early termination of treatment at week 6.
Nonetheless, we found that treatment with IFN-g–neutralizing anti-
bodies was able to restore the platelet levels in ARE-del mice close
to that in WT mice (supplemental Figure 6). When we examined the
Figure 5. The AA phenotype in ARE-del mice is not a result of a cell nonautonomous effect of IFN-g on the BMmicroenvironment. (A) The function of stromal cells in
ARE-del mice was determined by the serum levels of Flt3L, SCF, IL-3, IL-6, and EPO. The concentrations of cytokines were measured by using an enzyme-linked
immunosorbent assay and shown in bar graphs (n 5 6). BM phenotypes in WT.WT and ARE-del .WT mice were analyzed 8 weeks after reconstitution. (B) The bar graph
shows BM cell numbers of chimeric mice (n 5 6). (C) HSPC composition was analyzed on lineage-negative BM cells from WT.WT and WT.ARE-del mice by using flow
cytometry. Density plots are representative of HSPC gating from 1 set of 3 experiments. (D) Total BM cells from WT.WT and WT.ARE-del mice were stained with
fluorochrome-conjugated antibodies for lineage differentiation analysis. Dot plots are representative of 1 set of 3 experiments. Similar results were obtained from
3 different experiments. Results are expressed as mean 6 SD. *P , .05; **P , .01; ****P , .0001.
Table 2. BM transplant rescued AA-like phenotype in ARE-del mice
(n 5 6)
WT>WT (mean 6 SD) WT>ARE-del (mean 6 SD) P
WBC, K/mL 10.2 6 0.93 11.69 6 1.16 .34
RBC, M/mL 9.02 6 0.45 8.24 6 0.79 .38
Platelets, K/mL 703 6 40 605 6 58 .19
Blood was collected via heart puncture into tubes containing EDTA. CBC was
performed within 3 hours after collection.
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HSPC composition at the end of the treatment period, we found
that treatment with IFN-g–neutralizing antibodies restored the ARE-
delBMHSPCcomposition to closely resemble that inWTmice, from
high LT-HSCs and low CMPs, GMPs, and MEPs to low LT-HSCs
and high CMPs, GMPs, and MEPs (Figure 6F). The neutralizing
antibody treatment was also able to restore erythropoiesis in ARE-del
mice. We observed an increased percentage of mature eryth-
rocytes (R4) and reduced frequency of immature erythrocytes (R2)
compared with the ARE-del mice control group, indicating a
rescue of erythroid development (Figure 6G). These results dem-
onstrated that blocking IFN-g signaling ameliorates the throm-
bocytopenia and corrects the BM phenotype of ARE-del mice,
which further validates the role of IFN-g in AA pathology in
ARE-del mice.
Discussion
In this study, we provide evidence that IFN-g can lead to AA by
inhibition of hematopoiesis in a cell-intrinsic manner. During
hematopoiesis, MPPs differentiate into CMPs which differentiate
Figure 6. ARE-del>WT chimera mice exhibit early signs of BM failure with HSPC composition similar to that of ARE-del mice. BM phenotype of chimeric mice was
evaluated 8 weeks after reconstitution. (A) The bar graph shows the total BM cell number from WT.WT and ARE-del.WT (n 5 8). (B) T-cell population in BM of chimeric
mice was analyzed by using 7-color flow cytometry analyses. T cells were gated on live NKp46–CD11b–B220–Gr1–CD31 populations. Bar graphs show both the total cell
number of T cells and the percentage of live cells (n 5 8). (C) The function of T cells in chimeric BM was determined by the intensity of cytokine responses against TCR
agonists (anti-CD3/anti-CD28 antibodies [Abs]). Cytokine levels in the medium were measured 6 hours after stimulation by using a cytometric bead array. The bar graphs
displays the concentration of each cytokine measured (n 5 8). (D) HSPC composition in the BM of chimeric mice was analyzed on lineage– BM cells by using flow cytometry.
The bar graph shows the total cell number of each cell type (n 5 8). (E) Total BM cells from WT.WT and ARE-del.WT mice were stained with fluorochrome-conjugated
antibodies for lineage differentiation analysis. Dots plots are representative of 1 set of 3 experiments. (F) BM cells from all 4 groups (WT/control, WT/neutralizing, knockout
(KO)/control and KO/neutralizing) were analyzed for LSK and LK populations and (G) erythropoiesis. Density and dot plots are representatives of 1 set of 3 experiments.
Results are expressed as mean 6 SD. *P , .05; **P , .01; ****P , .0001
Table 3. ARE-del>WT chimera mice exhibited thrombocytopenia,
the first sign of BM failure (n 5 8)
WT>WT (mean 6 SD) ARE-del>WT (mean 6 SD) P
WBC, K/mL 9.08 6 0.63 7.5 6 0.69 .13
RBC, M/mL 11.12 6 0.16 10.4 6 0.68 .32
Platelets, K/mL 688 6 36 389.6 6 77 .0043
Blood was collected via heart puncture into tubes containing EDTA. CBC was
performed within 3 hours after collection.
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into GMPs and MEPs that give rise to myeloid cells, RBCs, and
platelets. IFN-g inhibits hematopoiesis by disrupting CMP gen-
eration and hampers the proliferation of CMPs, GMPs, andMEPs,
which would have a severe impact on hematopoiesis and even-
tually lead to an empty marrow and pancytopenia. Furthermore,
we observed disruptions of both B-cell and erythrocyte-lineage
differentiation in ARE-del mice, which further contributes to
the pathology of pancytopenia (supplemental Figure 7). We have
shown that the disruption in hematopoiesis in ARE-del mice is
not a result of a dysfunctional BM niche but rather a result of
a cell-intrinsic IFN-g inhibitory effect on HSPCs and lineage
differentiation. However, we cannot rule out the possibility that
IFN-g contributes to AA by affecting the BM microenvironment
in a nonhematopoietic-related fashion. Further studies are need-
ed to fully elucidate the possible effects of IFN-g on the BM
niche.
Among the reports on the impact of IFN-g on hematopoiesis, our
study is the first to identify the stages of hematopoiesis on which IFN-g
has an inhibitory effect. Similar to the result we report, Sellerri
et al have reported the inhibitory effect of IFN-g using an in vitro
culturing system with decreased cultured HSPC cell numbers and
functionality.26 Their results imply that IFN-g inhibits hematopoi-
esis in part by inducing apoptosis; however, we did not observe
such a phenomena in our mice. Maintenance of HSPCs requires
a specialized BMniche that is difficult to duplicate in vitro. Although
Sellerri and colleagues cultured HSPCs with stromal cells, that
system does not recapitulate the BM niche, which may explain the
difference in their observation regarding apoptosis. In addition,
we found that the strength of IFN-g signaling may account for
differences in the results. The phenotypes of ARE-del heterozygotes,
which express less IFN-g than ARE-del homozygotes, appear to be
normal. This observation implies that IFN-g signaling strength may
significantly contribute to the effect of IFN-g on hematopoiesis. The
IFN-g concentration used in Sellerri’s system is between 1 and
50 ng/mL, whereas the concentration in the BM plasma in our mice
is ;10 pg/mL (data not shown). It is possible that inducing
apoptosis requires stronger IFN-g signaling strength, which could
explain the lack of apoptosis in our system.
In addition to IFN-g, increased TNF-a expression has been as-
sociatedwithAAandwas shown to inhibit erythropoiesis in vitro.27-29
Because we could detect TNF-a in the serum of both ARE-del mice
and ARE-del.WT chimeras (data not shown), we cannot rule out the
involvement of TNF-a in AA pathology in ARE-del mice. However,
the observations that IFN-g suppresses the proliferation of CMPs and
MEPs in vitro and that neutralizing IFN-g restores erythropoiesis
indicate that IFN-g plays a role in erythropoiesis inhibition inARE-del
mice. However, the fact that TNF-a expression is stimulated by IFN-g
and that both cytokines activate nuclear factor kappa B make it diffi-
cult to identify which cytokine is causative. It is possible that the AA
pathology observed inARE-delmice is a result of synergistic inhibition
of IFN-g and TNF-a. Nonetheless, the notion that IFN-g and TNF-a
are found inARE-delmice further strengthens ourmodel, because both
cytokines can also be found in the BM plasma of AA patients.30
The majority of human AA is a consequence of autoreactive
T cells destroying HSPCs in the BM. In this study, we provide
evidence that deregulation of IFN-g alone could result in AA
pathology with a novel animal model that exhibits hypocellular
marrow and peripheral pancytopenia, which closely resembles
humanAA. However, unlike in humanAA, the pathology of ARE-
del mice is entirely IFN-g dependent, because we did not detect
either T-cell infiltration in BM or abnormal BM T-cell clonal
expansion. Because different levels of IFN-g have different
physiological outcomes,31,32 with the average IFN-g concentra-
tion in ARE-del BM plasma (;10 pg/mL) similar to the levels in
the BM of AA patients (,75 pg/mL),33 we believe that the ARE-
del model provides an opportunity to investigate and define the
physiological effects of endogenous IFN-g on hematopoiesis. In
addition, the unique characteristic of the ARE-del model, chronic
expression of IFN-g, also offers an opportunity to develop better
treatment options for AA patients by identifying and testing ap-
proaches to blocking chronic cytokine production.
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